Skip to content
Inciteful Med

Understanding the Diagnosis: Biology and Testing

Last updated:

Parkinson's disease is primarily diagnosed using the MDS Clinical Diagnostic Criteria, which requires the presence of slowness of movement (bradykinesia) combined with either tremor or stiffness. While no single blood test exists, a DaTscan can confirm dopamine loss to help distinguish Parkinson's from Essential Tremor.

Key Takeaways

  • • Parkinson's diagnosis is based on the MDS Clinical Diagnostic Criteria, not a single blood test.
  • • Bradykinesia (slowness of movement) is the core symptom required for a diagnosis.
  • • DaTscans effectively distinguish Parkinson's disease from Essential Tremor by visualizing dopamine loss.
  • • While mostly idiopathic, approximately 10-15% of Parkinson's cases are linked to genetic mutations like GBA or LRRK2.

Understanding how Parkinson’s disease (PD) is diagnosed requires looking at both the biology of the brain and the specific patterns of your symptoms. Unlike many other conditions, there is no single blood test that can definitively “prove” you have Parkinson’s; instead, it is a diagnosis built on clinical evidence and the exclusion of other possibilities [1].

The Biology: Oil for the Movement Engine

To understand Parkinson’s, it helps to think of your brain as a complex machine.

  • Dopamine is the “oil”: This chemical allows for smooth, coordinated movement. Without enough “oil,” the movement engine becomes stiff, slow, and prone to shaking [2].
  • The Substantia Nigra is the “factory”: Located deep in the brain, this area is responsible for producing dopamine. In Parkinson’s, the “factory workers” (neurons) in this area begin to die off [3].
  • Alpha-synuclein is the “trash buildup”: Scientists believe a protein called alpha-synuclein misfolds and clumps together, forming “trash piles” known as Lewy bodies. This buildup eventually prevents the neurons from working and causes them to fail [4].

By the time physical symptoms like a tremor appear, a significant portion of the dopamine-producing cells in the substantia nigra have already been lost [5].

How Doctors Diagnose PD: The MDS Criteria

Neurologists use a gold-standard framework called the MDS Clinical Diagnostic Criteria to make a diagnosis [6]. When tested against expert diagnosis, these criteria are highly accurate, with a sensitivity of 94.5% and a specificity of 88.5% [7]. The process involves three main steps:

  1. Confirming Parkinsonism: First, the doctor must see bradykinesia (slowness of movement). This must be accompanied by either a rest tremor (shaking when the limb is relaxed) or rigidity (stiffness) [6][8].
  2. Looking for Supportive Criteria: These are features that increase confidence in the diagnosis. The most important of these is an excellent response to Levodopa (a dopamine replacement medication) [7].
  3. Checking for Red Flags and Exclusions: The doctor looks for symptoms that don’t fit typical Parkinson’s, such as very early balance problems or rapid progression. These might suggest Atypical Parkinsonism, which are separate conditions that look like PD but progress differently [6].

Testing Tools: The DaTscan

While the diagnosis is primarily based on your physical exam, your doctor might order a DaTscan.

  • How it works: This is a specialized imaging test that uses a tracer to visualize the dopamine transporters in your brain [9][10].
  • What it shows: An abnormal scan confirms a loss of dopamine-producing cells. This is highly effective at distinguishing PD from Essential Tremor, where dopamine levels remain normal [11][12]. Modern analysis techniques can distinguish PD from non-PD subjects with an accuracy as high as 96% sensitivity [13].
  • What it can’t do: A DaTscan generally cannot tell the difference between typical Parkinson’s and Atypical Parkinsonisms, as both involve dopamine loss [14].

Genetics vs. “Idiopathic” Parkinson’s

Most cases of Parkinson’s (about 85-90%) are considered idiopathic, meaning the exact cause is unknown [15]. However, about 10-15% of cases are linked to specific genetic mutations [16]:

  • GBA: The most common genetic risk factor. It is associated with an earlier age of onset and a slightly faster progression of some symptoms [16][17].
  • LRRK2: A common cause of both familial (inherited) and sporadic (no family history) Parkinson’s [15].

Knowing your genetic status usually doesn’t change your current treatment, but it can help researchers develop targeted therapies for the future [18].

Feature Parkinson’s Disease Essential Tremor Atypical Parkinsonism
Primary Symptom Tremor at rest Tremor during action Early balance/speech issues
Dopamine Loss? Yes No Yes
DaTscan Result Abnormal Normal Abnormal
Levodopa Response Excellent Poor Poor or Transient
[11][7][19]

Frequently Asked Questions

How do doctors definitively diagnose Parkinson's disease?
Doctors use the MDS Clinical Diagnostic Criteria to diagnose Parkinson's. This involves a physical exam to look for slowness of movement (bradykinesia) combined with either resting tremor or stiffness. They also look for a positive response to Levodopa medication to confirm the diagnosis.
What is a DaTscan and why would I need one?
A DaTscan is a specialized imaging test that visualizes dopamine transporters in the brain. It is used to confirm the loss of dopamine-producing cells, which helps doctors distinguish Parkinson's disease from Essential Tremor (where dopamine levels remain normal).
Is Parkinson's disease genetic or hereditary?
Most cases of Parkinson's (about 85-90%) are "idiopathic," meaning the cause is unknown. However, about 10-15% of cases are linked to specific genetic mutations, such as changes in the GBA or LRRK2 genes.
What is alpha-synuclein and how does it affect the brain?
Alpha-synuclein is a protein that misfolds and clumps together in the brains of people with Parkinson's, forming "trash piles" called Lewy bodies. This buildup damages neurons in the substantia nigra, leading to dopamine loss and movement symptoms.

Questions for Your Doctor

  • • Based on the MDS criteria, am I considered to have 'clinically established' or 'clinically probable' Parkinson's?
  • • What specific 'red flags' or 'exclusion criteria' have you looked for in my case to rule out atypical parkinsonism?
  • • If we decide to do a DaTscan, how will the results change my current treatment plan?
  • • Are there specific signs in my physical exam that help distinguish my symptoms from Essential Tremor?
  • • Given my family history and age of onset, would you recommend genetic testing for GBA or LRRK2 mutations?

Questions for You

  • • Have you noticed a significant improvement in your movement symptoms after taking your Parkinson's medication?
  • • Did your symptoms (like a tremor or stiffness) start on just one side of your body, or did they appear on both sides at once?
  • • Beyond movement, have you noticed changes in your sense of smell, your sleep patterns, or your mood?
  • • Has anyone in your immediate family been diagnosed with Parkinson's, and at what age did their symptoms begin?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [New Diagnostic Criteria for Parkinson's Disease: MDS-PD Criteria].

    Watanabe H, Hara K, Ito M, et al.

    Brain and nerve = Shinkei kenkyu no shinpo 2018; (70(2)):139-146 doi:10.11477/mf.1416200966.

    PMID: 29433115
  2. 2

    Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

    Erkkinen MG, Kim MO, Geschwind MD

    Cold Spring Harbor perspectives in biology 2018; (10(4)) doi:10.1101/cshperspect.a033118.

    PMID: 28716886
  3. 3

    G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.

    Gaig C, Martí MJ, Ezquerra M, et al.

    BMJ case reports 2025; (2009()) doi:10.1136/bcr.08.2008.0632.

    PMID: 40780902
  4. 4

    [Atypical Parkinson's syndrome in old age].

    Iglseder B, Lange R

    Zeitschrift fur Gerontologie und Geriatrie 2022; (55(5)):421-430 doi:10.1007/s00391-022-02077-9.

    PMID: 35748931
  5. 5

    Progression marker of Parkinson's disease: a 4-year multi-site imaging study.

    Burciu RG, Ofori E, Archer DB, et al.

    Brain : a journal of neurology 2017; (140(8)):2183-2192 doi:10.1093/brain/awx146.

    PMID: 28899020
  6. 6

    MDS clinical diagnostic criteria for Parkinson's disease.

    Postuma RB, Berg D, Stern M, et al.

    Movement disorders : official journal of the Movement Disorder Society 2015; (30(12)):1591-601 doi:10.1002/mds.26424.

    PMID: 26474316
  7. 7

    Validation of the MDS clinical diagnostic criteria for Parkinson's disease.

    Postuma RB, Poewe W, Litvan I, et al.

    Movement disorders : official journal of the Movement Disorder Society 2018; (33(10)):1601-1608 doi:10.1002/mds.27362.

    PMID: 30145797
  8. 8

    Parkinsonism in essential tremor cases: A clinicopathological study.

    Rajput AH, Rajput EF, Bocking SM, et al.

    Movement disorders : official journal of the Movement Disorder Society 2019; (34(7)):1031-1040 doi:10.1002/mds.27729.

    PMID: 31180613
  9. 9

    Correlations between dopamine transporter density measured by 123I-FP-CIT SPECT and regional gray matter volume in Parkinson's disease.

    Maekawa T, Sato N, Ota M, et al.

    Japanese journal of radiology 2017; (35(12)):755-759 doi:10.1007/s11604-017-0694-z.

    PMID: 29063467
  10. 10

    Source-Based Morphometry Multivariate Approach to Analyze [123I]FP-CIT SPECT Imaging.

    Premi E, Calhoun VD, Garibotto V, et al.

    Molecular imaging and biology 2017; (19(5)):772-778 doi:10.1007/s11307-017-1052-3.

    PMID: 28194630
  11. 11

    [The applicability of 123I-FP-CIT SPECT dopamine transporter imaging in clinical practice].

    Perlaki G, Szekeres S, Janszky J, et al.

    Ideggyogyaszati szemle 2019; (72(11-12)):381-388 doi:10.18071/isz.72.0381.

    PMID: 31834681
  12. 12

    Relevance of 123I-FP-CIT SPECT prescriptions for the diagnosis of parkinsonian syndromes.

    Houot M, Arnaud S, Mongin M, et al.

    Scientific reports 2024; (14(1)):25088 doi:10.1038/s41598-024-73777-y.

    PMID: 39443529
  13. 13

    Clinical value of machine learning-based interpretation of I-123 FP-CIT scans to detect Parkinson's disease: a two-center study.

    Dotinga M, van Dijk JD, Vendel BN, et al.

    Annals of nuclear medicine 2021; (35(3)):378-385 doi:10.1007/s12149-021-01576-w.

    PMID: 33471288
  14. 14

    I123-FP-CIT (DaTSCAN) SPECT beyond the Most Common Causes of Parkinsonism: A Systematic Review.

    Quintas S, Sanles-Falagan R, Berbís MÁ

    Movement disorders clinical practice 2024; (11(6)):613-625 doi:10.1002/mdc3.14055.

    PMID: 38693679
  15. 15

    LRRK2 and mitochondria: Recent advances and current views.

    Singh A, Zhi L, Zhang H

    Brain research 2019; (1702()):96-104 doi:10.1016/j.brainres.2018.06.010.

    PMID: 29894679
  16. 16

    Mutations in the glucocerebrosidase gene are common in patients with Parkinson's disease from Eastern Canada.

    Han F, Grimes DA, Li F, et al.

    The International journal of neuroscience 2016; (126(5)):415-21 doi:10.3109/00207454.2015.1023436.

    PMID: 26000814
  17. 17

    GBA-Associated Parkinson's Disease and Other Synucleinopathies.

    Gan-Or Z, Liong C, Alcalay RN

    Current neurology and neuroscience reports 2018; (18(8)):44 doi:10.1007/s11910-018-0860-4.

    PMID: 29884970
  18. 18

    Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson's Disease.

    Braunger LJ, Knab F, Gasser T

    Journal of Parkinson's disease 2024; (14(5)):977-991 doi:10.3233/JPD-230408.

    PMID: 38848197
  19. 19

    Is Levodopa Response a Valid Indicator of Parkinson's Disease?

    Martin WRW, Miles M, Zhong Q, et al.

    Movement disorders : official journal of the Movement Disorder Society 2021; (36(4)):948-954 doi:10.1002/mds.28406.

    PMID: 33253432

This guide explains the criteria used to diagnose Parkinson's disease for educational purposes. Only a neurologist can confirm a diagnosis based on a physical exam and testing.

Stay up to date

Get notified when new research about Parkinson's Disease is published.

No spam. Unsubscribe anytime.